Pornthep ChanthavanichKriengsak LimkittikulChukiat SirivichayakulWatcharee ChokejindachaiWeerawan HattasinghKrisana PengsaaSurachai SurangsriratTermsang SrisuwannapornBenjawan KaewmaSutee YoksanGao JunBai ZhumuThailand Ministry of Public HealthMahidol UniversityLiaoning Cheng Da Biotechnology Co., Ltd.2019-08-232019-08-232018-04-03Human Vaccines and Immunotherapeutics. Vol.14, No.4 (2018), 900-9052164554X216455152-s2.0-85041813086https://repository.li.mahidol.ac.th/handle/20.500.14594/46024© 2018 The Author(s). Published with license by Taylor & Francis © 2018, © Pornthep Chanthavanich, Kriengsak Limkittikul, Chukiat Sirivichayakul, Watcharee Chokejindachai, Weerawan Hattasingh, Krisana Pengsaa, Surachai Surangsrirat, Termsang Srisuwannaporn, Benjawan Kaewma, Sutee Yoksan, Gao Jun, and Bai Zhumu. Summary: Inactivated mouse-brain-derived Japanese encephalitis vaccine has a worrisome safety profile and the live attenuated vaccine is unsuitable in immunodeficiency. This study aimed to evaluate the immunogenicity and safety of an inactivated chromatographically purified Vero-cell-derived JE vaccine (CVI-JE, Beijing P-3 strain) in children. 152 healthy Thai children, with an average (SD) age of 14.4 (3.8) months, received 3 doses of CVI-JE on days 0, 7–28, and one year. Homologous JE neutralizing antibody titers (NT) were measured. All subjects had seroprotection [geometric mean titer (GMT) 150] 28 days' post 2nd vaccination. The seroprotection rates at 1 year after primary series and and 1 month after the booster were 89.3% (GMT 49) and 100% (GMT 621), respectively. Local and systemic reactions–fever (17.6%), vomiting (8%), and poor appetite (5.3%)–were noted within 28 days' post-vaccination. All these symptoms were self-limited. Conclusions: CVI-JE is safe, immunogenic, and provided high NT.Mahidol UniversityImmunology and MicrobiologyMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1080/21645515.2017.1414763